rs772791252
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001352514.2(HLCS):c.2134C>T(p.Arg712*) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000156 in 1,607,176 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001352514.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HLCS | NM_001352514.2 | c.2134C>T | p.Arg712* | stop_gained | Exon 9 of 11 | ENST00000674895.3 | NP_001339443.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HLCS | ENST00000674895.3 | c.2134C>T | p.Arg712* | stop_gained | Exon 9 of 11 | NM_001352514.2 | ENSP00000502087.2 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152152Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251472Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135914
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1455024Hom.: 0 Cov.: 28 AF XY: 0.0000138 AC XY: 10AN XY: 724316
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152152Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74318
ClinVar
Submissions by phenotype
Holocarboxylase synthetase deficiency Pathogenic:8
- -
- -
- -
- -
- -
Variant summary: HLCS c.1693C>T (p.Arg565X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2e-05 in 246268 control chromosomes. c.1693C>T has been reported in the literature in individuals affected with Holocarboxylase Synthetase Deficiency (Sakamoto 1998, Tang 2003, Donti 2016). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal activity (Sakamoto_1998). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 426486). This premature translational stop signal has been observed in individual(s) with holocarboxylase synthetase deficiency (PMID: 9870216). This variant is present in population databases (rs772791252, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Arg565*) in the HLCS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HLCS are known to be pathogenic (PMID: 16134170). -
not provided Pathogenic:1
The R565X nonsense variant in the HLCS gene has been reported previously in association with holocarboxylase synthetase deciency in several unrelated individuals who were heterozygous for R565X and another variant in the HLCS gene (Sakamoto et al., 1998; Tang et al., 2003; Donti et al., 2016). This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at